Repeated insulin-like growth factor 1 treatment in a patient with Rett syndrome: A single case study

Frontiers in Pediatrics

Volumn 2, Issue JUN, 2014, Pages

  Pini, Giorgio ^a   Scusa, M Flora ^a   Benincasa, Alberto ^a   Bottiglioni, Ilaria ^a   Congiu, Laura ^a   Vadhatpour, Cyrus ^b   Romanelli, Anna Maria ^a   Gemo, Ilaria ^a   Puccetti, Chetti ^a   McNamara, Rachel ^b   O'Leary, Seán ^b   Corvin, Aiden ^b   Gill, Michael ^b   Tropea, Daniela ^a,b  

^a Versilia Hospital   (Italy)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Autonomic functions; Insulin like growth factor 1; Rett syndrome; Seizures; Social cognition

Indexed keywords

EID: 84969429020     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2014.00052     Document Type: Article

References (15)

1. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron (2007) 56:422-37. doi: 10.1016/j.neuron.2007.10.001
2. Percy A. Rett syndrome: a comprehensive review of the literature. Am J Ment Retard (1991) 96:275-90
3. Marschik PB, Kaufmann WE, Sigafoos J, Wolin T, Zhang D, Bartl-Pokorny KD, et al. Changing the perspective on early development of Rett syndrome. Res Dev Disabil (2013) 34:1236-9. doi:10.1016/j.ridd.2013.01.014
4. Kaufmann WE, Johnston MV, Blue ME. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution. Brain Dev (2005) 27(Suppl 1):S77-87
5. Cuddapah VA, Pillai RB, Shekar KV, Lane JB, Motil KJ, Skinner SA, et al. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet (2014) 51:152-8. doi:10.1136/jmedgenet-2013-102113
6. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A (2007) 104:1931-6. doi:10.1073/pnas.0610593104
7. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science (2007) 315:1143-7. doi:10.1126/science.1138389
8. McGraw CM, Samaco RC, Zoghbi HY. Adult neural function requires MeCP2. Science (2011) 333:186. doi:10.1126/science.1206593
9. Tropea D, Giacometti E, Wilson NR, Beard C, McCurry C, Fu DD, et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc Natl Acad Sci U S A (2009) 106:2029-34. doi:10.1073/pnas.0812394106
10. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron (2006) 49:341-8. doi:10.1016/j.neuron.2005.12.027
11. Castro J, Garcia R, Kwok S, Tropea D, Sur M. Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett syndrome. Society for Neuroscience Annual Meeting, New Orleans (2012)
12. Pini G, Scusa MF, Congiu L, Benincasa A, Morescalchi P, Bottiglioni I, et al. IGF1 as a potential treatment for Rett syndrome: safety assessment in six Rett patients. Autism Res Treat (2012) 2012:679801. doi:10.1155/2012/679801
13. Khwaja OS, Ho E, Barnes KV, O'Leary HM, Pereira LM, Finkelstein Y, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A (2014) 111:4506-601. doi:10.1073/pnas.1311141111
14. Galli-Tsinopoulou A, Nousia-Arvanitakis S, Tsinopoulos I, Bechlivanides C, Shevah O, Laron Z. Lanor syndrome. First report from Greece. Hormones (Athens) (2003) 2:120-4. doi:10.14310/horm.2002.1191
15. Kacinski M, Budziszewska B, Lason W, Zajac A, Skowronek-Bala B, Leskiewicz M, et al. Levels of S100 protein, neuron specific enolase, orexin A, adiponectin and insulin-like growth factor in serum of pediatric patients suffering from sleep disorders with or without epilepsy. Pharmacol Rep (2012) 64:1427-33. doi:10.1016/S1734-1140(12)70940-4